HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth
factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in …

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …

Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive
breast and gastric cancers, and are emerging as potential treatments for HER2-positive …

Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2
antibody conjugated with monomethyl auristatin E, in patients with HER2+ locally advanced …

Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …

CONTEXT: New data regarding treatment of muscle-invasive and metastatic bladder cancer
(MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) …

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from
cancer among men in the United States. Although guidelines assist in treatment, the art of …

Bladder cancer remains one of the most common and lethal diseases that cause
approximately 150,000 deaths per year worldwide. Over the past two decades, the options …

Purpose HER2 alterations are potential candidates for targeted treatments in metastatic
urothelial/bladder cancer (mUC). ERBB2 gene amplification and mutations are found in …